RAY1225 Injection Phase III Clinical Trials National Investigator Meeting Successfully Held: Embarking on a New Journey in Obesity and Diabetes Treatment
June 29, 2025, Beijing – Guangdong Raynovent Biotech Co., Ltd. ("Raynovent") successfully convened the National Investigator Meeting for three Phase III clinical trials of RAY1225 Injection. Focusing on two major therapeutic areas—overweight/obesity (REBUILDING-2) and type 2 diabetes (SHINING-2/3)—the meeting brought together over 300 principal investigators (PIs), researchers, and institutional representatives from more than 100 clinical centers
nationwide to Beijing in a hybrid format. Under the academic leadership of National Principal Investigator Professor Linong Ji from Peking University People's Hospital and Co-Leading PI Professor Li Yan from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, participants collaborated to ensure high-quality execution of the Phase III clinical program for RAY1225 Injection, China's innovative new drug candidate. Ms. Yuchong Zhang, actual controller of Zhongsheng Pharmaceutical Group, and Dr. Xiaoxin Chen, President of Raynovent, delivered opening remarks. Mr. Xuebing Qi, Chairman of Beijing Hygeia CRO, and Mr. Tiejun Cao, Chairman of Stamm Group, attended in support. The meeting was moderated by Mr. Haijun Li, Senior Vice President of Raynovent.
Focusing on Core Therapeutic Areas, Accelerating Clinical Development
Dr. Xiaoxin Chen, President of Raynovent, delivered the welcome address, introducing the company's R&D focus areas, strategic layout, pipeline portfolio, and key achievements. Dr. Chen noted that following the successful development and commercialization of two Class 1 innovative drugs—Leritavir tablets and Onradivir tablets—Raynovent has now prioritized RAY1225 Injection as its core focus for advancement toward market approval. "We look forward to working closely with Professor Ji, Professor Yan, and all experts, along with our partners, to fully advance the three Phase III clinical studies of RAY1225 Injection for weight loss and glucose control," Dr. Chen stated.
Leading Academic Guidance, Building a Solid Research Foundation
Professor Linong Ji from Peking University People's Hospital remarked in his address: "RAY1225, Raynovent's independently developed GLP-1/GIP dual receptor agonist with biweekly dosing characteristics, helps improve patient medication adherence. Recently presented at the American Diabetes Association (ADA) conference, Phase II data on glucose-lowering and weight-reduction demonstrated the drug's excellent pharmacokinetic profile and significant efficacy in both weight loss and glycemic control. The Phase III program aims to comprehensively validate its efficacy and safety. We hope this national investigator meeting will facilitate in-depth exchanges with researchers, jointly uphold research quality standards, and ultimately contribute a new chapter to diabetes and obesity treatment both domestically and globally."
Professor Li Yan from Sun Yat-sen Memorial Hospital added: "I am delighted to collaborate again with Professor Ji in leading the REBUILDING-2 study and to partner once more with the sponsor and clinical centers in developing this original Chinese Class 1 innovative drug. Our hospital has participated in RAY1225 Injection's clinical development from Phase I through Phase III. Raynovent's clinical team has demonstrated professionalism and efficiency, and RAY1225 has shown excellent safety and efficacy data. We look forward to the successful completion of the Phase III program."
Precise Protocol Interpretation, Upholding Quality Standards
Ms. Yun Peng, Senior Medical Director of Raynovent's Clinical Medicine Department, elaborated on RAY1225's design strategy, preclinical data, and clinical trial outcomes. Senior Medical Manager Ms. Jing Li and Medical Manager Ms. Ying Wu provided detailed interpretations of the protocol designs for the three Phase III studies in diabetes and overweight/obesity, respectively. Ms. Lixiang Ge, Project Director of Hygeia CRO, and Ms. Hongxia Wang, Project Director of Stamm Group, outlined project management workflows and subsequent implementation plans.
Professor Leili Gao from Peking University People's Hospital delivered an in-depth lecture on the management and documentation of gastrointestinal adverse events (GIAEs) associated with GLP-1 receptor agonists, covering GIAE characteristics, risk management measures, and adverse event recording protocols, providing scientific and practical solutions for risk prevention and control. Dr. Xia Xue and Dr. Nianrong Mi from Jinan Central Hospital shared valuable insights from their experience in RAY1225's Phase II trials for weight loss and glucose control, focusing on subject adherence and adverse event management.
Under the guidance of Professors Ji and Yan, investigators and institutional experts from participating centers actively contributed suggestions and engaged in lively discussions on critical topics including clinical protocol design, risk prevention and control, and clinical trial operational standards. The meeting successfully consolidated expert wisdom and practical experience, enhancing awareness and reaching consensus for the efficient and high-quality advancement of RAY1225's Phase III clinical trials.
PI's Heartfelt Message, Creating China's Excellence Together
Professor Linong Ji, National Principal Investigator and Chairman of Raynovent's Endocrinology and Metabolism Expert Committee, delivered the closing remarks. He highly commended the meticulous and in-depth discussions on the clinical protocols, reflecting the experts' professional expertise, rigorous scientific thinking, and pursuit of excellence in protocol details. Professor Ji extended special gratitude to the institutional representatives for their active participation, experience sharing, and valuable recommendations, emphasizing that the project's smooth progress and high-quality execution depend heavily on strong support from clinical trial institutions.
Professor Ji emphasized that clinical research requires close collaboration, thorough communication, and joint problem-solving among all parties. "RAY1225, as the world's first biweekly GLP-1/GIP dual agonist to enter Phase III clinical trials, demonstrates significant glucose-lowering and weight-reduction efficacy, offering patients a promising new therapeutic option and positioning itself for global academic recognition," he stated.
Group's Commitment to Innovation, Comprehensive Support and Safeguard
Ms. Yuchong Zhang, actual controller, Deputy Chairwoman, and Senior Vice President of Zhongsheng Pharmaceutical Group, delivered closing remarks, expressing profound respect to Leading PIs Professors Ji and Yan, and heartfelt gratitude to all attending experts and partner representatives. She noted that the meeting provided comprehensive reports on research background, protocol design, project progress, and risk management, and that the enthusiastic discussions and proactive suggestions from experts will significantly advance the smooth execution and high-quality completion of RAY1225 Injection's three Phase III studies.
Ms. Zhang emphasized that Zhongsheng Pharmaceutical Group steadfastly implements its strategic positioning of "Traditional Chinese Medicine as foundation, innovation-led, focusing on distinctive areas," continuously prioritizing and increasing R&D investment, with R&D expenditure consistently exceeding 12% of total sales revenue for consecutive years. The Group focuses on core therapeutic areas and strives for innovative breakthroughs. "The Group will provide comprehensive support to Raynovent in human resources, material resources, and financial resources, accelerating the innovative drug development process," Ms. Zhang affirmed.
"With heartfelt anticipation, under the joint leadership and guidance of Professors Ji and Yan, all participating parties will unite with shared commitment—maintaining reverence for scientific truth, pursuing research quality with excellence, and persevering in project efficiency—to accelerate the progress of RAY1225 Injection's Phase III clinical program, witness together the moment of RAY1225's new drug approval, and collectively contribute China's innovative strength to global health endeavors!" Ms. Zhang concluded. "We sincerely wish everyone good health, smooth work, and all the best!"
Key Attendees
The meeting featured distinguished experts including: